Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

Completed · Phase 3

Conditions studied: Prostatic Neoplasms

In brief

The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with prostate cancer, when administered as two injections twelve weeks apart.

Key facts

Study ID

NCT03261999

Run by

Foresee Pharmaceuticals Co., Ltd.

People needed

144

Starts

2017-09-26

Expected to finish

2019-02-01

Last updated by the study team

2020-05-04

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Males aged ≥ 18 years old
• Males with histologically confirmed carcinoma of the prostate
• Subjects who are judged by the attending physician and/or Principal Investigator to be a candidate for androgen ablation therapy
• Baseline morning serum testosterone level > 150 ng/dL performed at Screening Visit
• Eastern Cooperative Oncology Group (ECOG) Performance score ≤ 2
• Life expectancy of at least 18 months
• Laboratory values
• Absolute neutrophil count ≥ 1,500 cells/µL
• Platelets ≥ 100,000 cells/µL
• Hemoglobin ≥ 10 gm/dL
• Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
• AST (SGOT) ≤ 2.5 × ULN
• ALT (SGPT) ≤ 2.5 × ULN
• Serum creatinine ≤ 1.5 mg/dL
• Lipid profile within acceptable range according to investigator's opinion
• Serum glucose within acceptable range according to investigator's opinion
• HgbA1c within acceptable range according to investigator's opinion
• Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to investigator's judgment
• Serum glucose within acceptable range according to investigator's judgement
• Urinalysis within normal range according to the investigator's judgment
• Agree to use male contraceptive methods during study trial
• Based on the Investigator's judgment, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol
• All aspects of the protocol explained and written informed consent obtained

You may not qualify if…

• Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of carcinoma of the prostate. Radiation for pain control will be allowed during the study.
• Receipt of any vaccination (including influenza) within 4 weeks of screening visit
• History of blood donation within 2 months of screening visit
• History of anaphylaxis to any LH-RH analogues
• Receipt of any LHRH suppressive therapy within 6 months of screening visit
• Major surgery, including any prostatic surgery, within 4 weeks of screening visit
• History and concomitant clinical and radiographic evidence of central nervous system/spinal cord metastases and subjects at risk for spinal cord compression
• Clinical evidence of active urinary tract obstruction and subjects at risk for urinary obstruction
• History of bilateral orchiectomy, adrenalectomy, or hypophysectomy
• History or presence of hypogonadism, or receipt of exogenous testosterone supplementation within 6 months of Baseline
• Clinically significant abnormal ECG and/or history of clinically significant cardiovascular disease as judged by the investigator
• History of drug and/or alcohol abuse within 6 months of Baseline
• Contraindication to leuprolide or an LHRH agonist as indicated on package labeling
• Use of 5-alpha reductase inhibitor within the last 6 months of screening visit
• History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well controlled diabetes mellitus Type II will be allowed if only oral hypoglycemic are required. Prostate cancer subjects with poor controlled diabetes mellitus with Hb1Ac > 9.5% or urine glycosuria > 1.0 g/dL should be excluded.
• Use of systemic corticosteroids at a dose >10 mg/d or anti-androgens
• Use of any investigational agent within 4 weeks of screening visit
• Use of any over-the-counter (OTC) medication within 4 weeks of screening visit except for those listed in the permitted Concomitant Treatment section.
• Uncontrolled intercurrent illness that would jeopardize the subject's safety, interfere with the objectives of the protocol, or limit the subject's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor

Where it is running

• Urology Centers of Alabama — Homewood, Alabama, United States
• Arizona Institute of Urology — Tucson, Arizona, United States
• The Urology Center of Colorado — Denver, Colorado, United States
• Carolina Clinical Trials, LLC — Concord, North Carolina, United States
• Urology San Antonio, P.A — San Antonio, Texas, United States
• Urology of Virginia, PLLC — Virginia Beach, Virginia, United States
• Fakultní nemocnice Hradec Králové, Urologická klinika — Hradec Králové, Czechia
• Uromedical Center Olomouc — Olomouc, Czechia
• Thomayerova nemocnice, Urologické oddělení — Prague, Czechia
• Hospital of Lithuanian University of Health Sciences Kauno klinikos — Kaunas, Lithuania
• Klaipėda University Hospital — Klaipėda, Lithuania
• National Cancer Institute — Vilnius, Lithuania
• Vilnius University Hospital, Santaros klinikos — Vilnius, Lithuania
• UROCENTRUM MILAB, s.r.o. — Prešov, Slovakia
• Fakultná nemocnica s poliklinikou Žilina Urológia — Žilina, Slovakia
• Pusan National University Hospital — Busan, South Korea
• Keimyung University Dongsan Medical Center — Daegu, South Korea
• National Cancer Center — Gyeonggi-do, South Korea
• Seoul National University Bundang Hosptal — Gyeonggi-do, South Korea
• Hallym University Sacred Heart Hospital — Gyeonggi-do, South Korea
• Korea University Anam Hospital — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.